Solana Rendement FCF

Que fait Solana ? Helius Medical Technologies develops and markets the PoNS device, a portable neuromodulation stimulator for neurological wellness. The company focuses on non-invasive platform technologies that enhance the brain's healing ability. The PoNS device is authorized as a class II medical device in Canada for short-term treatment of chronic balance deficits caused by mild-to-moderate traumatic brain injury, used alongside physical therapy. It delivers non-invasive neurostimulation to the tongue to induce neuromodulation. Helius Medical Technologies targets healthcare providers and rehabilitation centers that treat patients with traumatic brain injury. The company's product is designed for use in clinical settings under professional guidance, specifically for patients requiring short-term balance deficit therapy. The PoNS device is positioned as a complementary treatment within physical therapy protocols for neurological rehabilitation. The firm's revenue model is based on the sale of the PoNS device to healthcare institutions and rehabilitation facilities. These institutions purchase the device for use in their treatment programs, leveraging its non-invasive neurostimulation technology to address balance deficits in patients with mild-to-moderate traumatic brain injury. The company's focus on neurological wellness through non-invasive solutions drives its commercial strategy. Solana est l'une des entreprises les plus populaires sur Eulerpool.